6261 - 6270 of 9104 Results
Title
Year
- Inconsistency and incongruence: the two diagnostic pillars of functional movement disorder2022RESTRICTEDTitle: Inconsistency and incongruence: the two diagnostic pillars of functional movement disorderJournal Name: The LancetPublisher: Elsevier BVVol: 400Issue #: 10348Start Page: 328End Page: 328Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0140-6736(22)01184-9Citation Count: 12
- Optimizing the reaction conditions for the GMP production of [18F]ACI-12589, a promising candidate in the development as a PET tracer targeting α-synuclein2022RESTRICTEDTitle: Optimizing the reaction conditions for the GMP production of [18F]ACI-12589, a promising candidate in the development as a PET tracer targeting α-synucleinJournal Name: Nuclear Medicine and BiologyPublisher: Elsevier BVVol: 108-109Issue #:Start Page: S87End Page: S88Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0969-8051(22)00207-4Citation Count: 0
- Mild and direct 18F radiofluorination of tetrazines through sulfonium salt precursors2022RESTRICTEDTitle: Mild and direct 18F radiofluorination of tetrazines through sulfonium salt precursorsJournal Name: Nuclear Medicine and BiologyPublisher: Elsevier BVVol: 108-109Issue #:Start Page: S88End Page: S89Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0969-8051(22)00209-8Citation Count: 0
-
OPENTitle: Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational studyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 3Start Page: 203End Page: 212Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30449-xBest OA location URL: http://hdl.handle.net/2445/214932Citation Count: 331
-
OPENTitle: Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trialJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 3Start Page: 182End Page: 192Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30489-0Best OA location URL: http://www.thelancet.com/article/S1474442220304890/pdfCitation Count: 137
-
OPENTitle: Prehospital scales in acute ischaemic stroke management – Authors' replyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 7Start Page: 504End Page: 505Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00169-1Best OA location URL: https://pure.eur.nl/en/publications/25abb6f2-0472-4754-8580-97e2533ac37aCitation Count: 1
- Movement disorders research in 2021: cracking the paradigm2021RESTRICTEDTitle: Movement disorders research in 2021: cracking the paradigmJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 1Start Page: 10End Page: 11Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00413-0Citation Count: 19
- Revisiting levodopa for advanced Parkinson's disease2022RESTRICTEDTitle: Revisiting levodopa for advanced Parkinson's diseaseJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1063End Page: 1065Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00435-5Citation Count: 2
- Major advances in Parkinson's disease over the past two decades and future research directions2022RESTRICTEDTitle: Major advances in Parkinson's disease over the past two decades and future research directionsJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1076End Page: 1079Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00448-3Citation Count: 18
- Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial2022RESTRICTEDTitle: Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trialJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1099End Page: 1109Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00400-8Citation Count: 204